Atogepant for migraine.

MedStar author(s):
Citation: Drugs of Today. 58(8):399-405, 2022 Aug.PMID: 35983926Department: Headache Fellowship | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Calcitonin Gene-Related Peptide Receptor Antagonists | *Migraine Disorders | Analgesics/tu [Therapeutic Use] | Calcitonin Gene-Related Peptide | Calcitonin Gene-Related Peptide Receptor Antagonists/tu [Therapeutic Use] | Humans | Migraine Disorders/dt [Drug Therapy] | Piperidines | Pyridines | Pyrroles | Spiro CompoundsYear: 2022ISSN:
  • 1699-3993
Name of journal: Drugs of today (Barcelona, Spain : 1998)Abstract: Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a key role in migraine. Medications targeting CGRP are being used as migraine preventive and abortive treatments. Copyright 2022 Clarivate.All authors: Ailani J, Bedrin KFiscal year: FY2023Digital Object Identifier: Date added to catalog: 2022-10-20
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 35983926 Available 35983926

Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a key role in migraine. Medications targeting CGRP are being used as migraine preventive and abortive treatments. Copyright 2022 Clarivate.

English

Powered by Koha